PBGH has joined USofCare by signing onto a letter to congressional leadership in calling for more funding for contact tracing in the upcoming coronavirus relief bill. Read the letter here.
PBGH joined 48 diverse business groups in signing onto a letter sent to Congressional Leadership urging Congress to include protections against surprise medical billing in the next COVID-19 package. Read the letter here.
The Pacific Business Group on Health has serious concerns with the price that Gilead has announced for remdesivir, a drug that reduces COVID-19 patients’ recovery time. Read the statement here.
Most major employers are embracing social distancing and other measures to safely bring employees back to work amid the new normal imposed by COVID-19, a recent Pacific Business Group on Health poll showed. See the results here.
The Coronavirus Aid, Relief, and Economic Security Act (S. 3548; H.R. 748), passed by Congress and signed into law today, is a very important step in the right direction at addressing the immediate needs of businesses and individuals. In this policy statement, PBGH calls on Congress and the Administration as it develops the next anticipated COVID-19 package to include the following provisions.
In a letter to Health and Human Services Secretary Alex Azar, the Pacific Business Group on Health calls on the Trump administration to address the urgent need to protect and strengthen independent primary care practices during the COVID-19 pandemic.
The Pacific Business Group on Health, as part of a coalition of physicians, consumer and business leaders, is calling on California state legislators to protect the very foundation of our health care system by supporting independent primary care providers vulnerable to the huge economic impacts of the COVID-19 pandemic.
Pacific Business Group on Health (PBGH) is pleased to announce Shawn Gremminger as Director, Health Policy beginning on March 16, 2020.
Employers’ Prescription for Affordable Drugs (EmployersRx) has announced its support of H.R. 5304, the “PBM Transparency and Prescription Drug Costs Act.” This bipartisan legislation will markedly lower private health insurance premiums and increase competition in the marketplace, according to a July 2019 report from the Congressional Budget Office.
Chairman Doggett, Ranking Member Nunes, and members of the House Ways and Means Health Subcommittee, thank you for the opportunity to provide a written statement for today’s hearing on behalf of the Employers’ Prescription for Affordable Drugs (EmployersRx), a coalition of employers united in advocacy to drive down the cost of prescription drugs—one of the biggest challenges in health care.